Uterine Fibroids

BioSpecifics and its clinical partners continue to analyze the full Phase 1 data to guide the design of a potential Phase 2 study of collagenase clostridium histolyticum (CCH) for the treatment of uterine fibroids.

Data from the Phase 1 clinical trial of CCH for the treatment of uterine fibroids were presented at the 66th Annual Meeting of the Society of Reproductive Investigation (SRI) on March 2019 in Paris, France. The reported data showed safety and statistically significant reductions in collagen content compared to control fibroids with a median reduction of 39 percent (p<0.05), as well as a 21 percent average reduction in density of collagen bundles.